Ralinepag
Pulmonary Arterial Hypertension (PAH)
Phase 3Active (ADVANCE CAP)
Key Facts
Indication
Pulmonary Arterial Hypertension (PAH)
Phase
Phase 3
Status
Active (ADVANCE CAP)
Company
About United Therapeutics
Founded on a personal mission to treat pulmonary arterial hypertension, United Therapeutics has grown into a diversified, multi-platform biotech leader with a $26B+ market cap. The company successfully commercializes a portfolio of PAH therapies while aggressively pursuing its 'Mozart' moonshot to create an unlimited supply of transplantable organs. This dual strategy balances near-term financial strength from its rare disease franchise with transformative, long-term value creation in organ manufacturing and regenerative medicine.
View full company profileOther Pulmonary Arterial Hypertension (PAH) Drugs
| Drug | Company | Phase |
|---|---|---|
| YUTREPIA™ (treprostinil) inhalation powder | Liquidia | Approved |
| LIQ861 (treprostinil) inhalation powder | Liquidia | Phase 3 |
| L606 (liposomal treprostinil) injection | Liquidia | Preclinical |
| NTP42 | ATXA Therapeutics | Phase 1 |
| Transdermal Treprostinil Prodrug Patch | Corsair Pharma | Pre-clinical |
| Anti-EMAP II monoclonal antibody | Allinaire Therapeutics | Pre-clinical |
| Tiprelestat | tiakis Biotech | Phase 2 |
| Seralutinib | Chiesi | Phase 3 |
| Sotatercept | Merck | Phase 3 |
| TPIP (Treprostinil Palmitil Inhalation Powder) | Insmed | Phase 2b |
| Beraprost MR | United Therapeutics | Phase 3 |
| CS1 | Cereno Scientific | Phase II |